A collaboration between Bristol-Myers Squibb and BioNTech resulted in an upfront cash payment on August 5, 2025.
4 reports, 2 independent
Updated Jul 21
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A collaboration between Bristol-Myers Squibb and BioNTech resulted in an upfront cash payment on August 5, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.BMS collaboration with BioNTech provided upfront cash payment on 2025-08-05.1 source
BioNTech established relationships with collaborators.1 source
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
BioNTech
Biotechnology company from Germany
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- GuruFocus.comBioNTech SE (BNTX) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... Total Revenue: EUR261 million for Q2 2025, up from EUR129 million in Q2 2024. Net Loss: EUR387 millio
- GlobeNewswireBioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025 MAINZ, Germany, July 21, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company